These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9809889)

  • 21. [Reflections on some methodological errors in the evaluation of drugs. Ten years experience at the National Marketing Authorization Commission].
    Bouvenot G
    Bull Acad Natl Med; 2001; 185(3):583-90; discussion 590-2. PubMed ID: 11501265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality.
    Gomberg-Maitland M; Frison L; Halperin JL
    Am Heart J; 2003 Sep; 146(3):398-403. PubMed ID: 12947355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mega-trials and equivalence trials: experience from the INJECT study.
    Hampton JR
    Eur Heart J; 1996 Sep; 17 Suppl E():28-34. PubMed ID: 11824001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.
    Mullins CD; Montgomery R; Abernethy AP; Hussain A; Pearson SD; Tunis S;
    J Clin Oncol; 2012 Feb; 30(6):661-6. PubMed ID: 22253467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Where to look for progress in antithrombotic treatments?].
    Samama MM
    Rev Prat; 1999 Oct; 49(15):1664-8. PubMed ID: 10581998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
    Naci H; Wouters OJ; Gupta R; Ioannidis JPA
    Milbank Q; 2017 Jun; 95(2):261-290. PubMed ID: 28589600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
    Kohberger RC
    Stat Med; 2009 Jan; 28(1):177-8, author reply 178-9. PubMed ID: 18937271
    [No Abstract]   [Full Text] [Related]  

  • 31. [The importance of equivalence trials in showing the usefulness of treatments].
    Hermens ML; van Hout HP; Terluin B; Adèr HJ; de Haan M
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2162-6. PubMed ID: 14626832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 4-Refining and monitoring antithrombotic therapies.
    Sharp CR; deLaforcade AM; Koenigshof AM; Lynch AM; Thomason JM
    J Vet Emerg Crit Care (San Antonio); 2019 Jan; 29(1):75-87. PubMed ID: 30654420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Methodology for superiority versus equivalence and non-inferior clinical studies. A practical review].
    Rosas-Peralta M; Santos-Martínez LE; Magaña-Serrano JA; Valencia-Sánchez JS; Garrido-Garduño M; Pérez-Rodríguez G
    Rev Med Inst Mex Seguro Soc; 2016; 54(3):344-53. PubMed ID: 27100981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of experimental design parameters on the determination of sample size.
    Jeffcoat M
    J Periodontal Res; 1992 Jul; 27(4 Pt 2):320-2. PubMed ID: 1507020
    [No Abstract]   [Full Text] [Related]  

  • 35. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The management of thrombosis in the antiphospholipid antibody syndrome: insights from recent clinical trials and remaining unsolved issues].
    Wahl D; Perret-Guillaume C; Piette JC
    Rev Med Interne; 2008 Sep; 29(9):731-4. PubMed ID: 18584919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence used for approval of new drugs.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
    Lisman T; Kamphuisen PW; Northup PG; Porte RJ
    J Hepatol; 2013 Aug; 59(2):358-66. PubMed ID: 23548197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical vs clinical significance in product testing: can they be designed to satisfy equivalence?
    Kingman A
    J Public Health Dent; 1992; 52(6):353-60. PubMed ID: 1432923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.